Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.
Roche’s pharma division chief Bill Anderson is to leave the Swiss giant after nearly 16 years at the company, including nearly three years as head of its flagship drugs business.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
